热景生物:公司与关联方拟共同投资尧景基因 公司出资2,400万元
HotgenHotgen(SH:688068) Ge Long Hui·2025-12-01 11:15

Core Viewpoint - The company, along with Lin Changqing and Beijing Yaojing Enterprise Management Center (Limited Partnership), plans to increase capital in Yaojing Gene, totaling 80 million yuan, which will enhance the long-term development of Yaojing Gene and improve the company's long-term investment returns [1] Group 1 - The capital increase consists of 24 million yuan from the company, 50 million yuan from Lin Changqing, and 6 million yuan from Beijing Yaojing Enterprise Management Center, totaling 80 million yuan [1] - The capital increase will change Yaojing Gene's registered capital from 110 million yuan to 150 million yuan [1] - The company's equity stake in Yaojing Gene will decrease from 40.91% to 38.00% after the capital increase [1] Group 2 - The transaction is expected to benefit the long-term development of Yaojing Gene [1] - It is stated that the capital increase will not affect the normal operation of the company or have a significant impact on its financial status and operating performance [1]